Compare ALH & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALH | DFTX |
|---|---|---|
| Founded | 1908 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.9B |
| IPO Year | 2025 | 2020 |
| Metric | ALH | DFTX |
|---|---|---|
| Price | $21.80 | $36.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $30.88 | ★ $38.50 |
| AVG Volume (30 Days) | 859.6K | ★ 2.0M |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $1,709,237,000.00 | N/A |
| Revenue This Year | $7.42 | N/A |
| Revenue Next Year | $5.88 | N/A |
| P/E Ratio | $34.47 | ★ N/A |
| Revenue Growth | ★ 13.31 | N/A |
| 52 Week Low | $18.64 | $14.62 |
| 52 Week High | $28.23 | $49.70 |
| Indicator | ALH | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.99 | 38.90 |
| Support Level | $21.05 | $16.37 |
| Resistance Level | $22.39 | $44.60 |
| Average True Range (ATR) | 0.58 | 1.87 |
| MACD | 0.13 | -0.08 |
| Stochastic Oscillator | 56.78 | 6.73 |
Alliance Laundry Holdings Inc is a designer and manufacturer of commercial laundry systems, serving diverse international markets. The company offers premium, durable laundry equipment under brands like Speed Queen, UniMac, Huebsch, Primus, IPSO, and others. It serves commercial laundry needs across healthcare, hotels, laundromats, and residential markets. Revenue is generated through the sale of commercial-grade laundry systems and service parts across two geographic segments, North America and International, and into the three end markets of OPL, Vended, and Commercial In-Home.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.